Up to week @ , the most common adverse events were upper respiratory tract infections ( four -LSB- @ % -RSB- , eight -LSB- @ % -RSB- , ten -LSB- @ % -RSB- , and seven -LSB- @ % -RSB- with secukinumab @ mg , @ mg , @ mg , and placebo , respectively ) and nasopharyngitis ( six -LSB- @ % -RSB- , four -LSB- @ % -RSB- , six -LSB- @ % -RSB- , and eight -LSB- @ % -RSB- , respectively ) .